Clinical Trials Browser

Phase 1 × INDUSTRY × Letrozole × Clear all

NCT06120283 2026-04-15

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Phase 1 Recruiting

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05307705 2026-03-27

PIKASSO-01

Phase 1 Active not recruiting

Breast Neoplasms

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT02499146 2026-02-11

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Phase 1 Completed

26 enrolled 40 charts

Advanced Breast Cancer

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Phase 1 Active not recruiting

Breast Neoplasms

NCT06570031 2025-07-02

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT03099174 2025-06-24

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Phase 1 Completed

133 enrolled 26 charts

Breast Neoplasms, Neoplasms

NCT06253195 2025-06-05

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT01296555 2024-07-31

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Phase 1 Terminated

674 enrolled 55 charts

Lymphoma, Non-Hodgkin

NCT01199367 2024-04-25

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT06367712 2024-04-16

Letrozole Alone Protocol Versus Using Letrozole and HCG Protocol

Phase 1 Completed

Polycystic Ovary Syndrome

NCT06047184 2023-09-21

Phase I Study of BEBT-209 in Women With Advanced Breast Cancer

Phase 1 Unknown

Advanced Breast Cancer

NCT02333370 2023-06-08

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Phase 1 Completed

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

NCT02684032 2022-07-27

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Phase 1 Completed

BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

NCT04856371 2021-04-23

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

Phase 1 Unknown

Advanced Breast Cancer

NCT02154776 2020-12-19

LeeBLet

Phase 1 Completed

Breast Neoplasms

NCT02093351 2019-10-02

To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer

Phase 1 Completed

79 enrolled 35 charts

Neoplasms

NCT01367626 2018-01-23

Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions

Phase 1 Completed

Breast Neoplasms

NCT01367652 2018-01-23

Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions

Phase 1 Completed

Breast Neoplasms

NCT00960960 2016-12-15

A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms